The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

Sogroya is gaining popularity among endocrinologists in the treatment of patients with growth failure. It's finally time to discuss the dynamics of Novo Nordisk's EPS changes. Earnings per share ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Novo Nordisk's 2024 earnings exceeded estimates ... thanks to the launch of Sogroya, a once-weekly treatment for growth hormone deficiency. As for blood disorders, sales also grew by 3%, boosted ...